<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535247</url>
  </required_header>
  <id_info>
    <org_study_id>HM-075</org_study_id>
    <nct_id>NCT02535247</nct_id>
  </id_info>
  <brief_title>Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2&#xD;
      explores the combination of copanlisib and pembrolizumab in patients with relapsed or&#xD;
      refractory NKTCL, who have received at least 1 prior systemic therapy. Cohort 2 will include&#xD;
      a phase 1 portion (cohort 2a) to determine the recommended phase 2 dose (RP2D) utilizing a&#xD;
      standard 3+3 design, followed by a phase II portion where patients will be treated at the&#xD;
      RP2D (cohort 2b). The primary endpoint for cohort 1 was progression-free survival; the&#xD;
      primary endpoint for cohort 2a will be to determine RP2D for the combination therapy; and&#xD;
      overall response rate at the end of 4 treatment cycles for cohort 2b. Patients will be&#xD;
      assessed for response with PET CT or CT every 12 weeks using the revised Cheson criteria.&#xD;
      Correlative endpoints will be exploratory and assess PD-1 expression on peripheral blood&#xD;
      lymphocytes; peripheral blood T-cell and NK-cell functional assays; PD-1 and PD-L1 expression&#xD;
      on tumor tissue; tumor infiltrating lymphocytes and gene expression panels using the&#xD;
      nanostring technology as prognostic and predictive biomarkers, as well as monitoring of&#xD;
      minimal residual disease via high-throughput sequencing of cell free tumor DNA, and exosome&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with relapsed or refractory (RR) NK and T-cell Lymphoma (NKTCL), who have received&#xD;
      at least 1 prior systemic therapy, were enrolled in cohort 1. The study design for cohort 1&#xD;
      was a single arm phase II 2-stage design, to explore monotherapy with the PD-1 antibody&#xD;
      pembrolizumab (or MK-3475) given intravenously at a fixed dose of 200mg every 3 weeks for up&#xD;
      to 36 cycles. Enrollment to this cohort has been completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 5, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks. Copanlisib is given intravenously at RP2D determined from Phase I study 18 in cohort 1 (pembrolizumab alone; completed); 27 in Cohort 2; 4-12 in cohort 2a (phase I); 18 in cohort 2b (phase II). Total up to 48</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose of the combination of pembrolizumab and copanlisib</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine Overall Response Rate by 4 cycles of combination of pembrolizumab and copanlisib</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose of pembrolizumab and copanlisib</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as the highest dose tested in which none or only one patient experienced dose-limiting toxicity (DLT) attributable to the study drug(s), when 6 patients have been treated at that dose and are evaluable for toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of PD-1, PD-L1 and tumor infiltrating lymphocytes (TIL) in pre-treatment tumor specimens</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-1 expression and leukocyte activation markers on circulating lymphocytes pre-treatment</measure>
    <time_frame>Week 3</time_frame>
    <description>PD-1 expression and leukocyte activation markers on circulating lymphocytes pre-treatment, at weeks 3 and 6, and at time of disease progression</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-1 expression and leukocyte activation markers on circulating lymphocytes pre-treatment</measure>
    <time_frame>Week 6</time_frame>
    <description>PD-1 expression and leukocyte activation markers on circulating lymphocytes pre-treatment, at weeks 3 and 6, and at time of disease progression</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lymphoma, T-Cell, Peripheral</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475</intervention_name>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Pembrolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib</intervention_name>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a histologically or cytologically confirmed relapsed/refractory mature T-cell&#xD;
             lymphoma that has progressed after a minimum of 1 systemic therapy with any of the&#xD;
             following T-cell histologies:&#xD;
&#xD;
               -  Peripheral T-cell NHL, not other wise specified (PTCL, NOS)&#xD;
&#xD;
               -  Anaplastic large cell T-cell lymphoma (ALCL)&#xD;
&#xD;
               -  Anaplastic lymphoma kinase positive or negative&#xD;
&#xD;
               -  Angioimmunoblastic T-cell lymphoma&#xD;
&#xD;
               -  Subcutaneous panniculitis like T-cell lymphoma&#xD;
&#xD;
               -  Follicular T-cell lymphoma&#xD;
&#xD;
               -  Nodal peripheral T-cell lymphoma with TFH phenotype&#xD;
&#xD;
               -  Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)&#xD;
&#xD;
               -  Enteropathy associated T-cell lymphoma&#xD;
&#xD;
               -  Hepatosplenic T-cell lymphoma&#xD;
&#xD;
               -  Extranodal NK/T-cell lymphoma, nasal type&#xD;
&#xD;
               -  Unclassifiable PTCL&#xD;
&#xD;
               -  Transformed cutaneous T-cell lymphoma (CTCL) to PTCL with systemic involvement&#xD;
                  (not local skin transformation).&#xD;
&#xD;
          2. Be willing and able to sign written informed consent for the trial.&#xD;
&#xD;
          3. Be at least 18 years of age on day of signing informed consent.&#xD;
&#xD;
          4. Have measurable disease based as defined by at least one lesion that can be measured&#xD;
             in least 2 perpendicular dimensions and measures at least 1.5 cm in its long axis.&#xD;
&#xD;
          5. Have provided tissue from an archival tissue sample or newly obtained core or&#xD;
             excisional biopsy of a tumor lesion obtained within 28 days prior to study enrollment.&#xD;
&#xD;
          6. Have a performance status of 0, 1 or 2 on the ECOG Performance Scale.&#xD;
&#xD;
          7. Demonstrate adequate organ function as defined below, all screening labs should be&#xD;
             performed within 10 days of treatment initiation.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) Greater than or equal to 1,500 /mcL, OR Greater&#xD;
                  than or equal to1,000 /mcL if lymphomatous bone marrow involvement Patients with&#xD;
                  documented marrow involvement may receive GCSF to achieve this value&#xD;
&#xD;
               -  Platelets greater than or equal to 100,000 / mcL, OR greater than or equal to&#xD;
                  75,000 / mcL if lymphomatous bone marrow involvement Patients with documented&#xD;
                  marrow involvement may be transfused to this value.&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 9 g/dL or greater than or equal to 5.6 mmol/L&#xD;
                  Patients with documented marrow involvement may be transfused to this value.&#xD;
&#xD;
               -  Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be&#xD;
                  used in place of creatinine or CrCl) less than or equal to1.5 X upper limit of&#xD;
                  normal (ULN) OR greater than or equal to 40 mL/min for subject with creatinine&#xD;
                  levels greater than 1.5 X institutional ULN&#xD;
&#xD;
               -  Serum total bilirubin less than 1.5 X ULN OR Direct bilirubin less than the ULN&#xD;
                  for subjects with total bilirubin levels greater than 1.5 ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) less than or equal to 2.5 X ULN OR less than or equal&#xD;
                  to 5 X ULN for subjects with liver involvement by lymphoma&#xD;
&#xD;
               -  Lipase less than or equal to 1.5 X ULN&#xD;
&#xD;
               -  International Normalized Ratio (INR) or Prothrombin Time (PT) less than or equal&#xD;
                  to 1.5 X ULN unless subject is receiving anticoagulant therapy&#xD;
&#xD;
               -  Activated Partial Thromboplastin Time (aPTT) less than or equal to 1.5 X ULN&#xD;
                  unless subject is receiving anticoagulant therapy as long as PT or PTT is within&#xD;
                  therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          8. Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of study medication (Reference&#xD;
             Section 5.5.2). Subjects of childbearing potential are those who have not been&#xD;
             surgically sterilized or have not been free from menses for greater than 1 year.&#xD;
&#xD;
          9. Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or using an investigational device within 2 weeks of the first dose of&#xD;
             treatment.&#xD;
&#xD;
          2. Patients diagnosed with Adult T-cell Leukemia/Lymphoma (ATLL) or T-cell PLL&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          4. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not&#xD;
             recovered (i.e., worse than Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., â‰¤ Grade 1 or at&#xD;
             baseline) from adverse events due to a previously administered agent.&#xD;
&#xD;
               -  Note: Subjects with worse than Grade 2 neuropathy are an exception to this&#xD;
                  criterion and may qualify for the study.&#xD;
&#xD;
               -  Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
          6. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy.&#xD;
&#xD;
          7. Has known active intraparenchymal lymphomatous central nervous system (CNS) lesions&#xD;
             and/or lymphomatous meningitis. Subjects with previously treated CNS involvement by&#xD;
             lymphoma may participate provided they are stable (without evidence of progression by&#xD;
             imaging for at least four weeks prior to the first dose of trial treatment and any&#xD;
             neurologic symptoms have returned to baseline), have no evidence of new or enlarging&#xD;
             brain lesions, and are not using steroids for at least 7 days prior to trial&#xD;
             treatment.&#xD;
&#xD;
          8. Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that&#xD;
             require intermittent use of bronchodilators or local steroid injections would not be&#xD;
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or&#xD;
             Sjoegren's syndrome will not be excluded from the study.&#xD;
&#xD;
          9. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
         10. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         11. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         12. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         13. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including&#xD;
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways).&#xD;
&#xD;
         15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         17. Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
         18. Cohort 2a: Has received an allogeneic stem cell transplant. For cohort 2b, patients&#xD;
             within the first 100 days of having undergone an allogeneic stem cell transplant will&#xD;
             be excluded. Otherwise, patients who have received an allogeneic stem cell transplant&#xD;
             are allowed as long as they have no evidence of active GVHD or are on&#xD;
             immunosuppressive therapy&#xD;
&#xD;
         19. Uncontrolled arterial hypertension despite optimal medical management&#xD;
&#xD;
         20. Uncontrolled Type I or II diabetes mellitus as deemed appropriate by the investigator.&#xD;
             Suggested guidelines for uncontrolled diabetes: HbA1c&gt; 8.5%&#xD;
&#xD;
         21. Anti-arrhythmic therapy (beta blockers or digoxin are permitted)&#xD;
&#xD;
         22. Use of CYP3A4 inhibitors and inducers. Copanlisib is primarily metabolized by CYP3A4.&#xD;
             Therefore concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole,&#xD;
             itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and&#xD;
             strong inducers of CYP3A (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St.&#xD;
             John's Wort) are not permitted from Day -14 of Cycle 1 until the Safety follow up&#xD;
             visit. See Table in Appendix 5 for complete list&#xD;
&#xD;
         23. Concurrent diagnosis of pheochromocytoma&#xD;
&#xD;
         24. Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within 3 months before the start of study medication&#xD;
&#xD;
         25. Prior exposure to PI3K inhibitors, unless on PI3K inhibitor therapy more than 6 months&#xD;
             ago AND reason for discontinuation of prior PI3K inhibitor therapy was other than&#xD;
             progression or toxicity.&#xD;
&#xD;
         26. Patients with detectable CMV viremia are excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

